ライフサイエンスコーパス: juvenile rheumatoid arthritis

1 (e.g., multiple sclerosis, sarcoidosis, and juvenile rheumatoid arthritis).

2 wel disease, autoimmune thyroid disease, and juvenile rheumatoid arthritis.

3 idate the etiopathogenesis of systemic onset juvenile rheumatoid arthritis.

4 equent MR imaging findings of knees in early juvenile rheumatoid arthritis.

5 ibody, in children with polyarticular-course juvenile rheumatoid arthritis.

6 , uveitis was associated with pauciarticular juvenile rheumatoid arthritis.

7 vement in patients with active polyarticular juvenile rheumatoid arthritis.

8 us option for the treatment of children with juvenile rheumatoid arthritis.

9 sorder that may be initially misdiagnosed as juvenile rheumatoid arthritis.

10 cantly to our understanding and treatment of juvenile rheumatoid arthritis.

11 c synovitis in both rheumatoid arthritis and juvenile rheumatoid arthritis.

12 vascular endothelium in the pathogenesis of juvenile rheumatoid arthritis.

13 crosis factor (TNF) has a pathogenic role in juvenile rheumatoid arthritis.

14 ntigen in patients with pauciarticular onset juvenile rheumatoid arthritis.

15 ize the recent data on biologic therapies in juvenile rheumatoid arthritis.

16 .64 [95% CI 0.86-6.17]) but not for systemic juvenile rheumatoid arthritis (1.8 [95% CI 0.66-3.92]).

17 /autoimmune diseases were identified: 2 with juvenile rheumatoid arthritis, 1 with Hashimoto thyroidi

18 Although systemic onset juvenile rheumatoid arthritis accounts for only about 20

19 ated with microarray data from patients with juvenile rheumatoid arthritis and healthy controls.

20 c lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, and the spondyloarthropat

21 The incidence of juvenile rheumatoid arthritis appears to fluctuate in a

22 therapies to treat rheumatoid arthritis and juvenile rheumatoid arthritis are approved and regulated

23 eported series, children with systemic onset juvenile rheumatoid arthritis are often the most difficu

24 ophage activation syndrome in systemic-onset juvenile rheumatoid arthritis as well.

25 s not been achieved to the same extent as in juvenile rheumatoid arthritis, but renal survival and ov

26 e dogma of the central role of the T cell in juvenile rheumatoid arthritis disease pathogenesis and o

27 CD4+ cells in the synovium of children with juvenile rheumatoid arthritis has led to the generally a

28 h clinical trials of etanercept in adult and juvenile rheumatoid arthritis have generally revealed fe

29 ng of the etiopathogenesis of systemic onset juvenile rheumatoid arthritis have led to therapies that

30 Many children with persistent systemic onset juvenile rheumatoid arthritis have marked physical and e

31 With the exception of juvenile rheumatoid arthritis, intravenous immunoglobuli

32 The heterogeneous nature of juvenile rheumatoid arthritis is further defined in publ

33 e most perplexing features of systemic-onset juvenile rheumatoid arthritis is the association with ma

34 uate the physical and psychosocial impact of juvenile rheumatoid arthritis (JRA) among a population-b

35 e is common in rheumatoid arthritis (RA) and juvenile rheumatoid arthritis (JRA) and can result in si

36 ere selected as prototypic for polyarticular juvenile rheumatoid arthritis (JRA) and pauciarticular/j

37 The immunopathogenic mechanisms of juvenile rheumatoid arthritis (JRA) have been debated.

38 ncommonly, some children with systemic-onset juvenile rheumatoid arthritis (JRA) have persistently ac

39 ne trends in the incidence and prevalence of juvenile rheumatoid arthritis (JRA) in Rochester, Minnes

40 creased over the prevalence of polyarticular juvenile rheumatoid arthritis (JRA) in the general popul

41 Juvenile rheumatoid arthritis (JRA) is a chronic systemi

42 One of the pathologic hallmarks of juvenile rheumatoid arthritis (JRA) is a tumor-like expa

43 Joint inflammation in juvenile rheumatoid arthritis (JRA) is sometimes associa

44 ls and matched peripheral blood samples from juvenile rheumatoid arthritis (JRA) patients using three

45 re present in the sera and synovial fluid of juvenile rheumatoid arthritis (JRA) patients.

46 atment in patients with polyarticular-course juvenile rheumatoid arthritis (JRA) provided rapid clini

47 Juvenile rheumatoid arthritis (JRA) remains a challenge

48 Juvenile rheumatoid arthritis (JRA) represents a heterog

49 as noted in early histopathologic studies of juvenile rheumatoid arthritis (JRA) synovium, the availa

50 s, clinical manifestations, and treatment of juvenile rheumatoid arthritis (JRA) that have appeared d

51 Synovial biopsy specimens from patients with juvenile rheumatoid arthritis (JRA) were used for additi

52 children with juvenile DM, 40 children with juvenile rheumatoid arthritis (JRA), or 23 healthy child

53 tibodies have been detected in patients with juvenile rheumatoid arthritis (JRA), particularly in tho

54 btypes of JIA are similar to the subtypes of juvenile rheumatoid arthritis (JRA).

55 only affected joints in severe, destructive, juvenile rheumatoid arthritis (JRA).

56 e IL-6 receptor are associated with systemic juvenile rheumatoid arthritis (JRA).

57 to disease-related factors in children with juvenile rheumatoid arthritis (JRA).

58 that the pathologic autoimmune responses in juvenile rheumatoid arthritis may be antigen-driven and

59 Chronic uveitis associated with juvenile rheumatoid arthritis may be less prevalent than

60 noses included rheumatoid arthritis (n = 8), juvenile rheumatoid arthritis (n = 3), ankylosing spondy

61 nic renal disease, obesity, type I diabetes, juvenile rheumatoid arthritis, obstructive sleep apnea,

62 rphalangeal joint erosions that mimic severe juvenile rheumatoid arthritis (OMIMs 166300, 259600, 259

63 reliminary core set of outcome variables for juvenile rheumatoid arthritis patients and a preliminary

64 s in children with cataracts associated with juvenile rheumatoid arthritis remains controversial, but

65 at there are important clues to the cause of juvenile rheumatoid arthritis to be gleaned from a more

66 sion protein, in children with polyarticular juvenile rheumatoid arthritis who did not tolerate or ha

67 anomalies born to a 20-year-old mother with juvenile rheumatoid arthritis who had been taking weekly

68 Patients 4 to 17 years of age with active juvenile rheumatoid arthritis who had previously receive

69 girl with a 3-year history of systemic-onset juvenile rheumatoid arthritis with a polyarticular cours

70 he more symptomatic knee in 30 children with juvenile rheumatoid arthritis with a symptom duration 1

71 toantibodies are a marker for pauciarticular juvenile rheumatoid arthritis with iridocyclitis, the pr